Literature DB >> 17530362

Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage.

Masato Yoneda1, Hironori Mawatari, Koji Fujita, Kyoko Yonemitsu, Shingo Kato, Hirokazu Takahashi, Hiroyuki Kirikoshi, Masahiko Inamori, Yuichi Nozaki, Yasunobu Abe, Kensuke Kubota, Satoru Saito, Tomoyuki Iwasaki, Yasuo Terauchi, Shinji Togo, Shiro Maeyama, Atsushi Nakajima.   

Abstract

BACKGROUND: The changes in nonalcoholic fatty liver disease range over a wide spectrum, extending from simple steatosis to nonalcoholic steatohepatitis (NASH). We investigated the clinical usefulness of the type IV collagen 7s domain and hyaluronic acid for predicting the severity of fibrosis before progression to the cirrhotic stage in NASH patients.
METHODS: The type IV collagen 7s domain and hyaluronic acid were measured in 72 patients with histologically verified NASH.
RESULTS: In a univariate analysis, marked elevation of hyaluronic acid and the type IV collagen 7s domain was observed in the NASH patients with advanced fibrosis compared with those with mild fibrosis (P = 0.0028, P = 0.0006, respectively). For detection of NASH with advanced fibrosis, the area under the receiver-operating characteristic curves for type IV collagen 7s domain and hyaluronic acid were 0.767 and 0.754, respectively. However, multiple regression analysis revealed that the type IV collagen 7s domain, but not hyaluronic acid, was significantly elevated in patients with advanced fibrosis even after adjustment for age, sex, platelet count, prothrombin time, aspartate aminotransferase/alanine aminotransferase ratio, body mass index, and presence of underlying type 2 diabetes mellitus, all of which have previously been reported as useful predictors of advanced fibrosis in patients with NASH (P = 0.0127, P = 0.2804, respectively).
CONCLUSIONS: This is the first report to demonstrate a consistent and profound elevation of the type IV collagen 7s domain in NASH patients with advanced fibrosis (before progression to the stage of cirrhosis) compared with those with mild fibrosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17530362     DOI: 10.1007/s00535-007-2014-3

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  31 in total

Review 1.  Appropriateness of liver biopsy.

Authors:  T Poynard; V Ratziu; P Bedossa
Journal:  Can J Gastroenterol       Date:  2000-06       Impact factor: 3.522

2.  Liver fibrosis in overweight patients.

Authors:  V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

3.  Correct homeostasis model assessment (HOMA) evaluation uses the computer program.

Authors:  J C Levy; D R Matthews; M P Hermans
Journal:  Diabetes Care       Date:  1998-12       Impact factor: 19.112

4.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

Review 5.  Nonalcoholic steatohepatitis.

Authors:  A E Reid
Journal:  Gastroenterology       Date:  2001-09       Impact factor: 22.682

6.  Significance of serum type-IV collagen levels in various liver diseases. Measurement with a one-step sandwich enzyme immunoassay using monoclonal antibodies with specificity for pepsin-solubilized type-IV collagen.

Authors:  T Ueno; S Inuzuka; T Torimura; H Oohira; H Ko; K Obata; M Sata; H Yoshida; K Tanikawa
Journal:  Scand J Gastroenterol       Date:  1992-06       Impact factor: 2.423

Review 7.  Clinical aspects of fatty liver disease.

Authors:  Jayanta Choudhury; Arun J Sanyal
Journal:  Semin Liver Dis       Date:  2004-11       Impact factor: 6.115

8.  Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.

Authors:  Jason M Hui; James G Kench; Shivakumar Chitturi; Archana Sud; Geoffrey C Farrell; Karen Byth; Pauline Hall; Mahbub Khan; Jacob George
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

Review 9.  Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?

Authors:  Geoffrey C Farrell
Journal:  J Gastroenterol Hepatol       Date:  2003-02       Impact factor: 4.029

10.  The natural history of nonalcoholic fatty liver: a follow-up study.

Authors:  M R Teli; O F James; A D Burt; M K Bennett; C P Day
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425

View more
  31 in total

Review 1.  Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.

Authors:  Jun Wei Lim; John Dillon; Michael Miller
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

2.  Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis.

Authors:  Kento Imajo; Masato Yoneda; Koji Fujita; Takaomi Kessoku; Wataru Tomeno; Yuji Ogawa; Yoshiyasu Shinohara; Yusuke Sekino; Hironori Mawatari; Yuichi Nozaki; Hiroyuki Kirikoshi; Masataka Taguri; Gen Toshima; Junichiro Takahashi; Satoru Saito; Koichiro Wada; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2013-03-16       Impact factor: 7.527

Review 3.  Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date.

Authors:  Somaya Albhaisi; Arun J Sanyal
Journal:  Pharmaceut Med       Date:  2019-12

Review 4.  Non-alcoholic fatty liver disease: what the clinician needs to know.

Authors:  Mariana Verdelho Machado; Helena Cortez-Pinto
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

5.  Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in Japan.

Authors:  Yoshio Sumida; Yuichiro Eguchi; Masafumi Ono
Journal:  World J Hepatol       Date:  2010-10-27

6.  A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease.

Authors:  Yoshio Sumida; Masato Yoneda; Hideyuki Hyogo; Kanji Yamaguchi; Masafumi Ono; Hideki Fujii; Yuichiro Eguchi; Yasuaki Suzuki; Shunsuke Imai; Kazuyuki Kanemasa; Koji Fujita; Kazuaki Chayama; Kohichiroh Yasui; Toshiji Saibara; Norifumi Kawada; Kazuma Fujimoto; Yutaka Kohgo; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2010-09-15       Impact factor: 7.527

7.  Magnitude of contrast-enhanced ultrasonography as a noninvasive predictor for hepatic fibrosis: comparison with liver stiffness measurement and serum-based models.

Authors:  Akinobu Tawada; Hitoshi Maruyama; Hidehiro Kamezaki; Taro Shimada; Hiroyuki Ishibashi; Masanori Takahashi; Tatsuo Kanda; Keiichi Fujiwara; Fumio Imazeki; Osamu Yokosuka
Journal:  Hepatol Int       Date:  2012-04-27       Impact factor: 6.047

8.  Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease.

Authors:  Masanori Abe; Teruki Miyake; Atsushi Kuno; Yasuharu Imai; Yoshiyuki Sawai; Keisuke Hino; Yuichi Hara; Shuhei Hige; Michiie Sakamoto; Gotaro Yamada; Masayoshi Kage; Masaaki Korenaga; Yoichi Hiasa; Masashi Mizokami; Hisashi Narimatsu
Journal:  J Gastroenterol       Date:  2014-10-18       Impact factor: 7.527

9.  Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation.

Authors:  Masato Yoneda; Yuichi Nozaki; Hiroki Endo; Hironori Mawatari; Hiroshi Iida; Koji Fujita; Kyoko Yoneda; Hirokazu Takahashi; Hiroyuki Kirikoshi; Masahiko Inamori; Noritoshi Kobayashi; Kensuke Kubota; Satoru Saito; Shiro Maeyama; Kikuko Hotta; Atsushi Nakajima
Journal:  Dig Dis Sci       Date:  2009-03-07       Impact factor: 3.199

10.  Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels.

Authors:  Masato Yoneda; Kento Imajo; Yuichiro Eguchi; Hideki Fujii; Yoshio Sumida; Hideyuki Hyogo; Masafumi Ono; Yasuaki Suzuki; Takumi Kawaguchi; Noriaki Aoki; Michio Sata; Kazuyuki Kanemasa; Yutaka Kohgo; Toshiji Saibara; Kazuaki Chayama; Yoshito Itoh; Toshikazu Yoshikawa; Keizo Anzai; Kazuma Fujimoto; Takeshi Okanoue; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2012-11-27       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.